Paclitaxel-eluting stents for the treatment of femoropopliteal arterial stenoses: focus on the Zilver PTX drug-eluting peripheral stent

References

• Savji N, Rockman CB, Skolnick AH, et al. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol 2013;61(16):1736-43
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47(6):1239-312
   PubMed Web of Science ®Google Scholar
• Rooke TW, Hirsch AT, Misra S, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;61(14):1555-70
   PubMedGoogle Scholar
• Kandarpa K, Becker GJ, Hunink MG, et al. Transcatheter interventions for the treatment of peripheral atherosclerotic lesions: part I. J Vasc Interv Radiol 2001;12(6):683-95
   Google Scholar
• Rocha-Singh KJ, Jaff MR, Crabtree TR, et al. Performance goals and endpoint assessments for clinical trials of femoropopliteal bare nitinol stents in patients with symptomatic peripheral arterial disease. Catheter Cardiovasc Interv 2007;69(6):910-19
   PubMed Web of Science ®Google Scholar
• Mwipatayi BP, Hockings A, Hofmann M, et al. Balloon angioplasty compared with stenting for treatment of femoropopliteal occlusive disease: a meta-analysis. J Vasc Surg 2008;47(2):461-9
   PubMed Web of Science ®Google Scholar
• Twine CP, Coulston J, Shandall A, McLain AD. Angioplasty versus stenting for superficial femoral artery lesions. Cochrane Database Syst Rev 2009(2):CD006767
   Google Scholar
• Duda SH, Bosiers M, Lammer J, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther 2006;13(6):701-10
   PubMed Web of Science ®Google Scholar
• Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: the SIROCCO II trial. J Vasc Interv Radiol 2005;16(3):331-8
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Paclitaxel-eluting stents show superiority to balloon angioplasty and bare metal stents in femoropopliteal disease: twelve-month Zilver PTX randomized study results. Circ Cardiovasc Interv 2011;4(5):495-504
   PubMed Web of Science ®Google Scholar
• Axel DI, Kunert W, Goggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96(2):636-45
   PubMed Web of Science ®Google Scholar
• Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109(6):701-5
   PubMed Web of Science ®Google Scholar
• Dake MD, Van Alstine WG, Zhou Q, Ragheb AO. Polymer-free paclitaxel-coated Zilver PTX Stents–evaluation of pharmacokinetics and comparative safety in porcine arteries. J Vasc Interv Radiol 2011;22(5):603-10
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. J Am Coll Cardiol 2013;61(24):2417-27
   PubMed Web of Science ®Google Scholar
• Dake MD, Scheinert D, Tepe G, et al. Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. J Endovasc Ther 2011;18(5):613-23
   PubMed Web of Science ®Google Scholar
• Fanelli F, Di Primo M, Boatta E, et al. Drug-eluting nitinol stent treatment of the superficial femoral artery and above-the-knee popliteal artery (the Zilver PTX single-arm clinical study): a comparison between diabetic and nondiabetic patients. Cardiovasc Intervent Radiol 2013;36(5):1232-40
   Google Scholar
• Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv 2013;6(3):274-81
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;45(Suppl S):S5-67
   PubMed Web of Science ®Google Scholar
• Bosiers M, Peeters P, Tessarek J, et al. The Zilver(R) PTX(R) Single Arm Study: 12-month results from the TASC C/D lesion subgroup. J Cardiovasc Surg (Torino) 2013;54(1):115-22
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Recently-Approved Devices > Zilver® PTX® Drug-Eluting Peripheral Stent - P100022. Available from: www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm330293.htm Last updated 17 January 2014 [Accessed 19 May 2014]
   Google Scholar
• U.S. Food and Drug Administration. Recalls, market withdrawals, & safety alerts > potential for delivery system catheter separation prompts cook medical to initiate voluntary global recall of Zilver® PTX® drug eluting stent. Available from: www.fda.gov/Safety/Recalls/ucm349421.htm Last updated 25 April 2013 [Accessed 19 May 2014]
   Google Scholar
• Ishihara T, Iida O, Awata M, et al. Angioscopic assessment of early phase arterial repair after paclitaxel-coated nitinol drug-eluting stent implantation in the superficial femoral artery. Circ J 2013;77(7):1838-43
   Google Scholar
• De Cock E, Sapoval M, Julia P, et al. A budget impact model for paclitaxel-eluting stent in femoropopliteal disease in France. Cardiovasc Intervent Radiol 2013;36(2):362-70
   PubMed Web of Science ®Google Scholar
• Evaluation of paclitaxel eluting stent vs paclitaxel eluting balloon treating peripheral artery disease of the femoral artery. Available from: http://clinicaltrials.gov/show/NCT01728441
   Google Scholar